Triple

Target class: constituency within the Generic Names Supporting Organization
Context triple: [Registrars Stakeholder Group, instanceOf, constituency within the Generic Names Supporting Organization]

• A. organ of the International Council for Harmonisation
  An organ of the International Council for Harmonisation is a formal body or component within the ICH structure that is responsible for developing, coordinating, or overseeing international guidelines and activities related to the harmonisation of pharmaceutical regulation.
• B. organ of the European Medicines Agency
  An organ of the European Medicines Agency is a formal decision-making or advisory body within the EMA’s governance structure, such as its Management Board, Executive Director, or scientific committees, responsible for specific regulatory, administrative, or scientific functions.
• C. public registry of clinical studies
  A public registry of clinical studies is an openly accessible database that records key information about planned, ongoing, and completed clinical research to promote transparency, accountability, and informed decision-making.
• D. generic drug manufacturer
  A generic drug manufacturer is a pharmaceutical company that produces bioequivalent, non-branded versions of patented or previously patented medications once exclusivity has expired, typically at lower cost.
• E. U.S. drug approval application type
  A U.S. drug approval application type is a regulatory category (such as NDA, BLA, or ANDA) that defines the specific pathway and requirements by which a sponsor seeks FDA authorization to market a drug or biologic.
• F. None of above. chosen